Thursday, November 10, 2022 9:54:50 PM
John Rodney Varner, Rodney R Varner, Rodney Te Varner, Rodney A Varner, Jrodney Rodney Varner, Rodney Varner Ave
Imagine you could go through life with this many alias?
Genprex firing of Michael T Redman is not enough?
John Rodney Varner has so far produce nothing but dilution buying and selling shares of Genprex Inc?
Or Rodney Varner? Whatever the hell he calls himself today?
Then pays himself almost a million a year to do so?
Is it a scam money laundering felony to obtain a shell with the sole purpose of dilution shares and paying yourself?
How else is Rodney John Varner John Varner Rodney paying himself?
Profit?
Is none?
Jail time has to be the only outcome if John aka Rodney aka JVarner is involved in faking studies to sell shares?
And judging by the raising O/S and his pay so far that's about all he is producing?
Am I wrong Johnathan? Johnny?
IMO
Everything I post, is In my own opinion, I don't care what you think about it, if you disagree, post it like I do. If you buy or sell stock based on what I say, your a lunatic and should not be trading. Have a great day!
Recent GNPX News
- Genprex to Present and Participate at Upcoming May Investor and Industry Conferences • PR Newswire (US) • 05/01/2024 12:31:00 PM
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 04/09/2024 12:31:00 PM
- Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer • PR Newswire (US) • 04/03/2024 12:31:00 PM
- Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System • PR Newswire (US) • 04/02/2024 12:31:00 PM
- Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/22/2024 08:10:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 05:24:00 PM
- Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/19/2024 12:36:00 PM
- Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 03/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:18:38 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting • PR Newswire (US) • 03/06/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:45:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:34:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:32:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:28:09 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators • PR Newswire (US) • 02/07/2024 01:15:00 PM
- Genprex to Present at Upcoming BIO CEO & Investor Conference • PR Newswire (US) • 02/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:15:59 PM
- Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer • PR Newswire (US) • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 12:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 02:00:20 PM
- Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 • PR Newswire (US) • 01/31/2024 01:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:17:02 PM
- Genprex Provides Business Update and Outlook for 2024 • PR Newswire (US) • 01/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:35:33 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM